Increased adiposity is a current concern in people living with HIV treated with the last-generation antiretroviral drugs of the integrase inhibitor family. The platform NAM-AIDSMAP, devoted to provision of independent, accurate & accessible information about HIV, highlights our findings recently published in Life Sciences (doi: 10.1016/j.lfs.2022.120948). We showed that the integrase inhibitor dolutegravir suppresses the production of adiponectin, a chemical secreted by fat tissue that regulates insulin sensitivity, which provides further evidence that dolutegravir can have direct effects on the human cells that store fat (see